-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AAA-603 in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AAA-603 in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AAA-603...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AAA-614 in Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AAA-614 in Colorectal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AAA-614 in Colorectal Cancer Drug Details: 3B-201 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AAA-614 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AAA-614 in Solid Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AAA-614 in Solid Tumor Drug Details: 3B-201 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AAA-614 in Soft Tissue Sarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AAA-614 in Soft Tissue Sarcoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AAA-614 in Soft Tissue Sarcoma Drug Details: 3B-201 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AAA-614 in Pancreatic Ductal Adenocarcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AAA-614 in Pancreatic Ductal Adenocarcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AAA-614 in Pancreatic Ductal Adenocarcinoma Drug Details: 3B-201 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AAA-614 in Adenoid Cystic Carcinoma (ACC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AAA-614 in Adenoid Cystic Carcinoma (ACC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AAA-614 in Adenoid Cystic Carcinoma (ACC) Drug Details: 3B-201 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AAA-802 in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AAA-802 in Metastatic Castration-Resistant Prostate Cancer (mCRPC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AAA-802 in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AAA-817 in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AAA-817 in Metastatic Castration-Resistant Prostate Cancer (mCRPC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AAA-817 in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Drug Details:...
-
Product Insights
NewEndologix LLC Pipeline Insight and Competitive Landscape, 2023
Empower your strategies with our Endologix LLC Pipeline Insight and Competitive Landscape, 2023 report and make more profitable business decisions. Endologix LLC (Endologix) is a medical equipment company that develops, manufactures and markets minimally invasive devices in treatment of aortic diseases. The company incorporates its patented technology for the treatment of Abdominal Aortic Aneurysms (AAA) and ALTO Abdominal Stent Graft System . The company’s AAA products are built on traditional minimally invasive endovascular repair (EVAR) platform or endovascular sealing (EVAS)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lutetium Lu 177 Vipivotide Tetraxetan in Metastatic Prostate Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lutetium Lu 177 Vipivotide Tetraxetan in Metastatic Prostate Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lutetium Lu 177 Vipivotide Tetraxetan in...